Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lean Body Mass as a determinant of docetaxel pharmacokinetics and toxicity (LEANDOC)
2011-005168-14Phase 4Terminated
- Sponsor
- Radboud University Medical Center
- Start
- Feb 2012
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of docetaxel in breast cancer and metastatic castration-resistant prostate cancer (mCRPC), sponsored by Radboud University Medical Center. Primary endpoint: Correlation between anthropometric measures and docetaxel exposure. Started Feb 2012; status: terminated.
02
Drugs
docetaxel
03
Conditions
breast cancermetastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2011-005168-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005168-14.